{
  "outcomes_metadata": {
    "timestamp": "2025-09-08T14:27:19.516910",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "consolidation_type": "outcomes",
    "total_unique_outcomes": 28,
    "source_countries": [
      "DE",
      "DK",
      "EN",
      "FR",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        {
          "name": "Overall survival (OS)",
          "details": [
            "Median OS, hazard ratio (HR), 12-month OS rate, indirect comparison HR, median OS extension",
            "Defined as time from randomisation to death from any cause",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), NL (clinical_guideline), EN (clinical_guideline), SE (clinical_guideline)"
          ]
        },
        {
          "name": "Event-free survival",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        },
        {
          "name": "Prolonged survival",
          "details": [
            "Reported in: SE (clinical_guideline)"
          ]
        }
      ],
      "response_measures": [
        {
          "name": "Objective response rate (ORR)",
          "details": [
            "Primary endpoint; includes overall response rate; measured by RECIST 1.1 criteria in some sources",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), NL (clinical_guideline), DK (clinical_guideline), EN (clinical_guideline)"
          ]
        },
        {
          "name": "Duration of response (DoR)",
          "details": [
            "Median DoR",
            "Reported in: PT (hta_submission), DK (clinical_guideline)"
          ]
        },
        {
          "name": "Disease control rate (DCR)",
          "details": [
            "Reported in: PT (hta_submission), PO (hta_submission)"
          ]
        },
        {
          "name": "Response to immunotherapy monotherapy",
          "details": [
            "Reported in: DK (clinical_guideline)"
          ]
        }
      ],
      "progression_measures": [
        {
          "name": "Progression-free survival (PFS)",
          "details": [
            "Median PFS, HR, 12-month PFS rate, subgroup analyses by ECOG status and metastasis location, defined as time from randomisation until disease progression or death from any cause, assessed by blinded independent central review",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), NL (clinical_guideline), DK (clinical_guideline), EN (clinical_guideline)"
          ]
        },
        {
          "name": "Time to progression",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        },
        {
          "name": "Time to next treatment",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        },
        {
          "name": "Time to progression on subsequent therapy",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        },
        {
          "name": "Duration of treatment",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        }
      ]
    },
    "safety": {
      "adverse_events": [
        {
          "name": "Adverse events (AEs)",
          "details": [
            "Measured by CTCAE v5.0 in some sources; includes total AEs, treatment-related AEs, frequency of specific AEs (diarrhoea, increased ALT/AST, fatigue, anaemia, constipation, neutropenia, fever, alopecia, stomatitis, peripheral oedema, peripheral neuropathy, blood and lymphatic system disorders, infections and infestations)",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), NL (clinical_guideline), DK (clinical_guideline), EN (clinical_guideline)"
          ]
        },
        {
          "name": "Dose modification-related adverse drug reactions (ADRs)",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        }
      ],
      "serious_events": [
        {
          "name": "Serious adverse events (SAEs)",
          "details": [
            "Includes Grade 3-4 AEs, severe AEs, treatment-related AEs resulting in death, interstitial lung disease (severe AE), liver disorders (severe AEs)",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), DK (clinical_guideline)"
          ]
        },
        {
          "name": "Potential risk of serious side effects on the skin",
          "details": [
            "Reported in: FR (clinical_guideline)"
          ]
        },
        {
          "name": "Mortality-related toxicity",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        }
      ],
      "discontinuations": [
        {
          "name": "Discontinuation rate due to adverse events",
          "details": [
            "Includes treatment discontinuation due to AEs, treatment-related AEs leading to discontinuation",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission)"
          ]
        }
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        {
          "name": "Quality of life (QoL)",
          "details": [
            "Overall health status/quality of life; measured by EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D VAS, BPI-SF, FACT-G GP5, PGI-C; includes assessment of symptoms (pain, swelling, dyspnea, hair loss, chest bleeding, cough); stable or deterioration reported; change from baseline to week 12; higher functional score = deterioration, higher general health = improvement",
            "Reported in: PT (hta_submission), PO (hta_submission), DE (hta_submission), NL (clinical_guideline), EN (clinical_guideline), SE (clinical_guideline)"
          ]
        },
        {
          "name": "Health-related quality of life",
          "details": [
            "Reported in: EN (clinical_guideline)"
          ]
        },
        {
          "name": "Preservation of quality of life",
          "details": [
            "Reported in: SE (clinical_guideline)"
          ]
        }
      ],
      "functional_status": [
        {
          "name": "Time to deterioration of overall health status",
          "details": [
            "Reported in: PT (hta_submission), PO (hta_submission)"
          ]
        },
        {
          "name": "Time to deterioration of physical functioning",
          "details": [
            "Reported in: PT (hta_submission)"
          ]
        },
        {
          "name": "Karnofsky or ECOG performance status",
          "details": [
            "Consideration of patient overall condition",
            "Reported in: DE (clinical_guideline)"
          ]
        }
      ],
      "symptom_measures": [
        {
          "name": "Symptom control",
          "details": [
            "Reported in: SE (clinical_guideline)"
          ]
        },
        {
          "name": "Symptomatology and health status",
          "details": [
            "Assessed by EORTC QLQ-C30, EORTC QLQ-LC13, BPI-SF, FACT-G GP5, PGI-C",
            "Reported in: DE (hta_submission)"
          ]
        }
      ]
    },
    "economic": {
      "cost_effectiveness": [
        {
          "name": "Incremental cost-utility ratio (ICUR)",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        },
        {
          "name": "Cost-utility analysis (CUA)",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        }
      ],
      "utilities": [
        {
          "name": "Utilities (as part of cost-utility analysis)",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        }
      ],
      "resource_utilization": [
        {
          "name": "Budget impact analysis (public payer perspective)",
          "details": [
            "Reported in: PO (hta_submission)"
          ]
        }
      ]
    },
    "other": {
      "exploratory_endpoints": [
        {
          "name": "Treatment according to evidence-based recommendations",
          "details": [
            "Reported in: DE (clinical_guideline)"
          ]
        },
        {
          "name": "Use of targeted therapy (Sotorasib)",
          "details": [
            "Reported in: DE (clinical_guideline)"
          ]
        },
        {
          "name": "Consensus-based recommendation",
          "details": [
            "Reported in: DE (clinical_guideline)"
          ]
        }
      ],
      "biomarkers": [],
      "pharmacokinetics": []
    }
  }
}